

Supplementary Figure 3

**A** UC endoscopic remission: Mayo endoscopic score = 0

	test positive	LL-37 above 32ng/ml		CRP 0.4mg/L or below		LL-37 above 32ng/ml + CRP 0.4mg/L or below	
	test negative	any others		any others		any others	
		mean	(95% CI interval)	mean	(95% CI interval)	mean	(95% CI interval)
prevalence		0.27	0.14 0.46	0.23	0.11 0.43	0.30	0.15 0.50
sensitivity		1.00	0.63 1.00	0.71	0.30 0.95	1.00	0.63 1.00
specificity		0.38	0.20 0.59	0.30	0.14 0.53	0.38	0.19 0.61
PPV		0.38	0.20 0.59	0.24	0.09 0.48	0.41	0.21 0.63
NPV		1.00	0.63 1.00	0.78	0.40 0.96	1.00	0.60 1.00
AUC		0.76		0.71		0.84	

**B** Severe UC endoscopic activity: Mayo endoscopic score = 3

	test positive	LL-37 below 60ng/ml		CRP above 0.5 mg/L		LL-37 below 60ng/ml + CRP above 0.5 mg/L	
	test negative	any others		any others		any others	
		mean	(95% CI interval)	mean	(95% CI interval)	mean	(95% CI interval)
prevalence		0.15	0.06 0.33	0.13	0.04 0.32	0.13	0.04 0.32
sensitivity		1.00	0.46 1.00	0.75	0.22 0.99	0.75	0.22 0.99
specificity		0.32	0.17 0.52	0.77	0.56 0.90	0.85	0.64 0.95
PPV		0.21	0.08 0.43	0.33	0.09 0.69	0.43	0.12 0.80
NPV		1.00	0.63 1.00	0.95	0.74 0.99	0.96	0.76 1.00
AUC		0.59		0.71		0.80	

**C**

		E1	E2	E3	biologics	steroids	immunomodulators	5-ASA
LL-37 32 ng/ml or below	count	0	5	1	2	2	2	3
	percentage	0	83	17	33	33	33	50
LL-37 above 32 ng/ml	count	8	26	12	5	10	9	26
	percentage	19	60	28	12	23	21	60

		E1	E2	E3	biologics	steroids	immunomodulators	5-ASA
LL-37 below 60ng/ml	count	7	24	7	7	16	7	23
	percentage (%)	18	60	18	16	37	16	54
LL-37 60ng/ml or above	count	1	7	6	2	2	5	10
	percentage (%)	7	50	43	14	14	36	71

General disease phenotypes: Montreal classification of UC

- E1 Ulcerative proctitis
- E2 Left side UC (distal UC)
- E3 Extensive UC (pancolitis)